Dupilumab (Dupixent) for the treatment of eczema in adults
In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether dupilumab has any advantages or disadvantages compared to optimized individual treatment for moderate to severe in adults who are able to have systemic treatment.
The manufacturer provided one suitable study involving 425 adults whose data could be used in the analysis. Of those patients, 110 used dupilumab for about a year and 315 used a placebo (fake medication). In addition, both groups had treatment with glucocorticoid (steroid) creams. If their symptoms got worse, the treatment was individually adjusted further. The study included only people who had had moderate to severe for at least three years.